Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 29, 2025, titled "Strides Delivers a Strong Q1FY26 with ₹11,197m Revenue, ₹2,181m EBITDA, and ₹1,140m Operational PAT".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science reported Q1FY26 revenue of ₹11,197m, up 6.2% year-on-year. Gross margin expanded 300bps to 60.3%, driving EBITDA up 14.8% YoY to ₹2,181m with margin at 19.5% (up 150bps). Operational PAT jumped 80.6% YoY to ₹1,140m, with operational EPS at ₹12.4 versus ₹6.9 last year. US business revenue grew 7% YoY to $71m, while the company maintained a US business outlook of ~$400m by FY27-28. Net debt reduced by ₹264m to ₹14,958m, ROCE stood at 15.1%, and credit rating was upgraded to 'CARE A Positive'. Note: Q1FY25 figures were restated following the demerger of the Softgel business.
Strong quarterly performance with healthy margin expansion, record PAT, and improving balance sheet metrics is a positive signal for shareholders. Credit rating upgrade and debt reduction suggest improving financial health, though sequential revenue dipped 5.9% QoQ and Access Markets remain weak due to donor funding issues.